Piper Sandler analyst David Amsellem downgraded Intra-Cellular (ITCI) to Neutral from Overweight with a price target of $132, up from $107, citing the pending acquisition by Johnson & Johnson (JNJ). Piper does not expect a higher bid given that the 39% premium to Intra-Cellular’s closing price on January 10 “more than adequately reflects not only the top-line potential of Caplyta but also what are likely to be massive cost synergies.”
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITCI:
- Intra-Cellular downgraded to Market Perform from Outperform at Leerink
- BofA moves to No Rating on Intra-Cellular after Johnson & Johnson deal
- Intra-Cellular downgraded to Neutral from Outperform at Baird
- J&J to acquire Intra-Cellular, Clearwater to buy Enfusion: Morning Buzz
- Biotech Alert: Searches spiking for these stocks today